Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-life use of delamanid: results from the European post-authorisation safety study.
Schönfeld N, Barkane L, Davoliene I, Danilovits M, Miliauskas S, Ader F, Kon OM, Lange C, Duvignaud A, Heiss-Neumann M, Hittel N, Lazarević N, Knebel I, Martin A, Eschenbach B, van Heumen E, George V. Schönfeld N, et al. Among authors: hittel n. IJTLD Open. 2024 Jun 1;1(6):274-278. doi: 10.5588/ijtldopen.24.0113. eCollection 2024 Jun. IJTLD Open. 2024. PMID: 39021446 Free PMC article.
Developing biomarker assays to accelerate tuberculosis drug development: defining target product profiles.
Gillespie SH, DiNardo AR, Georghiou SB, Sabiiti W, Kohli M, Panzner U, Kontsevaya I, Hittel N, Stuyver LJ, Tan JB, van Crevel R, Lange C, Thuong TNT, Heyckendorf J, Ruhwald M, Heinrich N. Gillespie SH, et al. Among authors: hittel n. Lancet Microbe. 2024 Sep;5(9):100869. doi: 10.1016/S2666-5247(24)00085-5. Epub 2024 May 9. Lancet Microbe. 2024. PMID: 38735303 Free article. Review.
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.
von Groote-Bidlingmaier F, Patientia R, Sanchez E, Balanag V Jr, Ticona E, Segura P, Cadena E, Yu C, Cirule A, Lizarbe V, Davidaviciene E, Domente L, Variava E, Caoili J, Danilovits M, Bielskiene V, Staples S, Hittel N, Petersen C, Wells C, Hafkin J, Geiter LJ, Gupta R. von Groote-Bidlingmaier F, et al. Among authors: hittel n. Lancet Respir Med. 2019 Mar;7(3):249-259. doi: 10.1016/S2213-2600(18)30426-0. Epub 2019 Jan 7. Lancet Respir Med. 2019. PMID: 30630778 Clinical Trial.
23 results